What is HC Wainwright’s Estimate for TBPH FY2024 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for Theravance Biopharma in a research report issued on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.01) for the year. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.43) EPS.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $9.08 on Thursday. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90. The business has a fifty day moving average of $9.35 and a two-hundred day moving average of $8.91. The stock has a market cap of $446.50 million, a PE ratio of -8.99 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TBPH. Aquatic Capital Management LLC acquired a new stake in Theravance Biopharma during the 4th quarter valued at $25,000. Quantbot Technologies LP bought a new stake in shares of Theravance Biopharma during the third quarter worth $60,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Theravance Biopharma in the fourth quarter valued at $69,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 3,696 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new position in shares of Theravance Biopharma in the fourth quarter valued at about $103,000. Institutional investors own 99.10% of the company’s stock.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.